- EvokAI (TSXV:OKAI) began the CE Mark certification process for its MDM Flex Sensor to transform the management of Parkinson’s disease
- EvokAI’s technology leverages state-of-the-art advancements in medical technology to provide more effective and personalized care for Parkinson’s disease and related movement disorders
- The technology aims to address challenges such as monitoring the level and frequency of the tremors 24/7
- Shares of EvokAI last traded at C$1.35
EvokAI (TSXV:OKAI) began the CE Mark certification process for its MDM Flex Sensor to transform the management of Parkinson’s disease.
EvokAI’s technology leverages advancements made in medical technology to provide more effective and personalized care for Parkinson’s disease and related movement disorders.
The technology aims to address challenges such as monitoring the level and frequency of the tremors 24/7. It also includes remote monitoring capabilities, enabling healthcare professionals to closely track patients’ progress and make timely adjustments to their treatment plans.
“Parkinson’s disease is a complex neurodegenerative disorder affecting millions worldwide, the initiation of the CE Mark certification is a significant step towards making the MDM Flex Sensor available to patients in Europe and beyond, Alejandro Antalich, CEO of EvokAI Creative Labs, said in a statement. “The development of our cutting-edge technology in collaboration with one of the most prestigious research institutions in the world, VTT Technical Research Centre of Finland, underscores our commitment to excellence and innovation. This partnership has provided us with access to world-class expertise, state-of-the-art facilities, and a collaborative environment that fosters groundbreaking discoveries.”
Testing and certification is expected to be complete by Q4 2023. EvokAI plans to make its Parkinson’s technology available to patients across Europe.
Operating out of Vancouver, EvokAI Creative Labs is a med-tech AI company developing technologies for the healthcare industry.
The company’s AI algorithms are intended for hospitals, private clinics, research institutions, pharmaceutical companies, medical professionals and patients, among many others.
Shares of EvokAI last traded at C$1.35 and OKAI stock is up 216.8 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this stock on the EvokAI Creative Stock Forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.